- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
F10 Humanized Mouse Model
| Strain Name | F10 Humanized Mouse Model |
|---|---|
| Editing Type | Humanize/Knockin |
| Gene Name | F10 (mouse) / F10 (human) |
| Gene Synonyms | Mouse: fX; Cf10|Human: FX; FXA |
| Strain Background | C57BL/6N |
| NCBI No. | Gene ID: 14058 / MGI:103107(mouse) |

1. Coagulation and thrombosis Investigate the role of human factor X in the intrinsic and extrinsic pathways, thrombin generation, and pathological thrombosis. Evaluate its pathophysiological contribution in thrombotic disease, including atherosclerosis and deep vein thrombosis.
2. Anticoagulant drug development and evaluation Evaluate the pharmacodynamics, pharmacokinetics, and bleeding risk of direct oral anticoagulants (rivaroxaban, apixaban) and other inhibitors targeting human factor Xa in vivo. Because human and mouse FXa differ at the active site, the humanized background allows DOAC potency to be measured at concentrations relevant to patients rather than at the compensatory doses required in wild-type mice. Study the therapeutic effect of factor Xa inhibitors across thrombosis models.
3. Factor X deficiency — autosomal recessive, OMIM #613872 Model reduced factor X activity or dysfunction to study the bleeding phenotype of factor X deficiency and the efficacy of replacement approaches, including the iron deposition and cardiac fibrosis documented in severe murine deficiency.
Hemophilia A and B are X-linked deficiencies of factor VIII and factor IX, respectively, and are not reproduced by factor X reduction. This strain is relevant to those programs only as a downstream readout background, since factor X activation is the step that FVIII/FIX replacement ultimately restores.
4. Hemostasis and acquired coagulopathy Investigate how human factor X changes in acquired coagulation disorders such as trauma, surgery, and liver disease. Assess its role in balancing physiological hemostasis against pathological hyperfibrinolysis.
The F10 Humanized Mouse Model is generated by replacing the mouse F10 coding region with the human F10 sequence, so that mice express functional human coagulation factor X. Factor X is a vitamin K–dependent serine protease synthesized in hepatocytes and serves as the convergence point of the intrinsic and extrinsic pathways: it is activated by factor IXa or factor VIIa to form factor Xa, which converts prothrombin to thrombin in the presence of factor Va, calcium, and phospholipid. Because FXa activity sets the rate of thrombin generation, the humanized model allows the catalytic behavior of the human enzyme—its active-site pharmacology, substrate handling, and cofactor requirements—to be studied in a living animal rather than extrapolated from murine data. The strain supports mechanistic work on thrombosis and hemostatic balance, preclinical evaluation of human-FXa-directed anticoagulants, and characterization of factor X deficiency and replacement strategies.
1. Human FXa active site in vivo. Human and mouse factor Xa differ sufficiently at the catalytic domain that DOAC potency measured in wild-type mice does not translate cleanly to patients. Expressing the human enzyme removes that gap.
2. Reads out the convergence point. PT, APTT, and thrombin-generation assays all converge at factor X, so a single genetic change reports on both pathways.
3. Dose–response for anticoagulants. Bleeding time, thrombus formation, and thrombin generation can be measured across a dose range without first saturating murine FXa.
4. Disease-side modeling. Reduced-activity alleles can be introduced to reproduce factor X deficiency phenotypes, including the iron deposition and cardiac fibrosis reported in severe murine deficiency.
5. Stackable with other humanized factors. Can be combined with additional humanized coagulation factors on request.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.
